title: Efficacy of pregabalin in the management of cetuximab-related itch.
authors.forename: Giampiero
authors.initials: G
authors.lastname: Porzio
authors.forename: Federica
authors.initials: F
authors.lastname: Aielli
authors.forename: Lucilla
authors.initials: L
authors.lastname: Verna
authors.forename: Claudio
authors.initials: C
authors.lastname: Porto
authors.forename: Marianna
authors.initials: M
authors.lastname: Tudini
authors.forename: Katia
authors.initials: K
authors.lastname: Cannita
authors.forename: Corrado
authors.initials: C
authors.lastname: Ficorella
mesh_terms: D000700:Analgesics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068818:Cetuximab; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069583:Pregabalin; D011537:Pruritus / Q000139:chemically induced* / Q000188:drug therapy*; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000700:Analgesics; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D000068818:Cetuximab